None
Conditions
Interventions
Laser group (exposure group):Minimally invasive extraction of the IMM3 followed by debridement of the MM2.Er:YAG Laser
Control group (non exposed group):Minimally invasive extraction of the IMM3 followed by debridement of the MM2. Sham laser procedure
Sponsors
Stomatology Hospital,Zhejiang University School Medicine
Eligibility
Sex/Gender
All
Age
26 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.Age 26–50 years, either gender, requiring extraction of an impacted mandibular third molar (IMM3); 2.Classified as mesioangular or horizontal impaction according to the Winter classification, with partial submucosal or bony impaction, and in close proximity to the second molar (MM2); 3.Preoperative cone beam computed tomography (CBCT) reveals >=4 mm of bone defect on the distal aspect of the MM2 adjacent to the IMM3—i.e., the distance from the distal cemento-enamel junction (CEJ) of MM2 to the base of the alveolar bone defect is >=4 mm, and there is a site with maximum probing depth (PD) >=6 mm on the distal aspect of MM2; 4.The patient voluntarily participates in this clinical trial with good compliance and can attend follow-up visits on schedule; 5.The patient can conscientiously maintain cleanliness and oral hygiene in the surgical area postoperatively.
Exclusion criteria
Exclusion criteria: 1.Patients whose MM2 cannot be preserved due to grade III mobility, tooth fracture, history of inadequate root canal treatment, or severe periapical inflammation; 2.Patients with factors affecting radiographic evaluation of MM2 or those with caries on the distal cervical area of MM2; 3.Patients with acute inflammation in the surgical site, such as pericoronitis or mandibular alveolar abscess; 4.Patients with dentigerous cysts around the IMM3, other oral and maxillofacial tumors, or those undergoing treatment for such tumors; 5.Patients with a history of diabetes mellitus, alcoholism, hematological disorders, smoking, psychiatric disorders, or other severe systemic diseases; 6.Patients who are pregnant, lactating, or planning pregnancy; 7.Patients undergoing orthodontic treatment; 8.Patients who are unable to comply with medical instructions, cooperate with the trial, resulting in incomplete trial procedures or data recording that may affect efficacy evaluation; 9.Patients requiring removal of buccal or lingual bone walls during IMM3 extraction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage reduction in probing depth at 6 months (PD reduction, ?PD%); | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events;Pain intensity at the surgical site;Plaque index;Gingiva recession;Level of inflammatory factors;Bleeding on probing;Percentage reduction in probing depth (?PD%) at 3 and 12 months postoperatively.;Change in bone defect height;Frequency and dosage of analgesic use;Rate of bone height change; | — |
Countries
China
Contacts
Public ContactQianting Wang
Stomatology Hospital,Zhejiang University School Medicine
Outcome results
None listed